CDKN2A and gastric neoplasm: Three pan-cancer cohorts (the MSK MetTropism, TCGA, and OrigiMed 2020 cohorts) found high CDKN2A ALT rates and significant survival effects in esophageal/stomach cancer, and Smita Sihag et al. found that CDKN2A had strong association with poor OS in 487 esophageal/stomach cancer patients with targeted sequencing [45].